Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All I expect to learn Monday is the AS and OS. Why do you think the future will be revealed? Why set yourself up for disapointment?
I guess we should know by Monday, 4-15-24 unless there is another extension.
I am starting to believe that it's more than just blue light from screens and lighting that causes DED. I think that the prolification of BT and WiFi may also be related.
There is also the NPTX ticker and the variable AXIM notes that need to be converted when the acumulation phase wraps up.
Blue, why delay the AS/OS information? There has to be a reason.
The only thing I can come up with is a merger.
AXIM and Verséa must be in some type of merger discussions. But my gut is telling me AXIM and Verséa might be in discussions with a third party with a little more financial backing. NOT a Big Pharma. But a third company where AXIM and Verséa still control the consolidated company.
I keep thinking about the delay in shareholder information and this is the only thing that makes sense.
I keep looking at AXIM at different angles to see if I'm being foolish for investing here.
I might be foolish. That is a possibility.
Let me just admit to that.
HOWEVER, if my tiny investment is foolish then multiply that by 100 or 200 or 1000 or whatever the multiple is and that is what Catalina Valencia pulled out of her pocket maybe 15 months ago.
When I see that kind of commitment from Catalina Valencia my thoughts are not "IF" but "WHEN" AXIM is profitable. That was some rock solid commitment from Catalina Valencia.
15 million shares times zero still equals zero.
25 million shares times zero still equals zero.
Just remember that Catalina Valencia made her investment after Doctor Rob Sambursky was brought in as an advisor by the AXIM BOD. Then Dr Sambursky was hired as a VP by Verséa Health and President of Verséa Ophthalmics.
Maybe the plan is taking longer than expected.
Customers and sales are increasing every week.
I am keeping an eye on this ticker. Appreciate all the great DD you post here.
No debate on that point.
It has been a long time.
However I will argue that AXIM is closer now than ever before.
^^ Two FDA cleared 510K Dry Eye disease Diagnostic tests.
^^ Marketing agreement with a very knowledgeable and energetic sales team in Verséa Ophthalmics
^^ Manufacturing agreement with an ISO-13485 certified manufacturer in Auer Precision who seems perfect to help with the AXIM and Verséa Ophthalmics national roll-out.
^^ Sales increasing every month.
^^ Two more Tear-based Point-of-Care tests in the pipeline MMP-9 and Parkinson Disease tests.
What is the old saying?
"Close only counts in horse shoes and hand grenades"
Let's hope for a lucky horse shoe with the CLIA Waiver Application and Approval. Maybe with Verséa Health's experience we don't need luck. But if the FDA doesn't approve a Waiver this will be a slow path.
I've been here since the first beginning with Dr George. It's been a long road.
It's only been what...couple years already?
So that's why some of the employees like Jessica has an address on their business cards that was essentially a mail drop at a shared office in Tampa.
Verséa Health already expanded their office and warehouse space in 2023. Here is that press release from May 8th of last year. I think Kurt Phinney was responsible for helping with the expansion process.
First paragraph:
"plan to add 40 new jobs over the next 2-3 years."
https://www.versea.com/versea-health-inc-expansion-to-a-larger-facility-in-tampa-fl/
I have to believe much of that expansion will be dedicated to supporting the Verséa Ophthalmics division.
I believe AXIM and Verséa Ophthalmics and Auer Precision have all been following a planned roll-out. The CLIA Waivers are maybe the last steps before the flood gates are opened. Hopefully those last steps happen sooner than later.
Wow Tex! You think volume will increase sufficiently that Versea will need to expand their warehouse and accounting infrastructure? That's a lot of readers and tests.
This eye doctor will be announced as a new customer this week or very soon. He seems very excited about getting started with the new TPOC testing system.
https://www.linkedin.com/posts/kyledkluteod_optometry-optometry-optometrists-activity-7182089642018578432-SGx6?utm_source=share&utm_medium=member_android
I started following Kyle Klute on LinkedIn. He seems like a Verséa Ophthalmics sales representative. He is that excited!!
Not investment advice.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Bottom line is Verséa has resources that understand how to interact with the FDA.
Verséa knows how to submit CLIA Waivers and have them approved. It has only been 3+ months since manufacturing started at Auer Precision. At some point Verséa Ophthalmics will have a priority to help AXIM with the CLIA Waiver Application process. Something tells me there is a schedule that needs to be followed.
What needs to happen BEFORE CLIA Waivers are approved??
A few things I can think of are listed:
Auer Precision will need to ramp up manufacturing to meet the explosion of new customers.
AXIM and Verséa Ophthalmics will need hundreds or thousands of the new test readers that are manufactured in Spain.
Verséa Ophthalmics would need to ramp up their support teams. Warehouse, Sales, Accounting, Customer support.
I'm sure there are other considerations.
Blue, thanks for sharing the CLIA Waiver information from Verséa Health!!
AXIM and Verséa Ophthalmics are following a plan. A lot of things need to happen BEFORE turning on the flood of new orders.
At least the FDA is moving faster when CLIA Waivers are submitted.
Not investment advice.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Both of them look the same so it looks like it took just over 2 months for both. One can dream though. I just wish Bigcharts would start working correctly. I wasted so much time this morning trying to get charts to update I didn't give this enough time.
I see the following dates.
My impression is 510K date
Date Received 04/12/2023
Decision Date 06/16/2023
2 months which is still awesome.
Then 1 year later the Waiver approval
Complexity WAIVED
Effective Date 04/04/2024
Versea has a lot of these under their belt. This is something that they clearly know how to get done.
The approval shows
Date received
Date approved
My assumption is that date received is the application date.
How did you find the Application Date?
I can't find how you came up with 4 days.
Great news for Verséa Diagnostics and Verséa Health.
Versea got a few positive decisions from the FDA published today. This one for example https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/Detail.cfm?ID=40027 with WAIVED approved 4 days after the application. That would imply that Versea could submit the wavier request on Monday hours after the 10K is released and have an approval on Friday of next week that would be published by the FDA the following Monday April 22. This one as well WAIVED in 4 days. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/Detail.cfm?ID=40028 These were categorized as substantially similar SESE so they were apparently the fastest to process but it seems that the FDA is moving very rapidly these days.
What is #ISO13485 and why is it important?
What is ISO 13485 and why it is important?
https://www.linkedin.com/pulse/what-iso-13485-why-important-sublimemanagement-06btf?utm_source=share&utm_medium=member_android&utm_campaign=share_via
AXIM’S manufacturing partner Auer Precision is #ISO13485 certified and #ISO9001 certified. The previous video by Auer Precision shows what a great choice AXIM made on December 20th 2023 signing Auer Precision as our manufacturing partner. That was literally just 3.5 months ago. A lot has happened over the last 3 months. The pace of only one new customer a week seems slow, but after just 3.5 months the big picture is a lot brighter today than 4 months ago.
Not investment advice.
Please do your own research.
Don't invest money needed for food or rent or happiness.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Great new video about Auer Precision from about 2 months ago.
https://www.linkedin.com/posts/marvin-russell-084a88_trailblazing-precision-a-journey-through-activity-7182385821071601664-xkWI?utm_source=share&utm_medium=member_android
Hashtags related to AXIM Biotech and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
More links related to the news a few days ago.
West Point Optical with 86 Pearle Vision locations signs exclusive #Biovance and #Biovance3L supply agreement with Verséa Ophthalmics .
https://www.visionmonday.com/business/article/west-point-optical-group-llc-and-versa-ophthalmics-inc-announce-partnership-supply-agreement/
https://www.businesswire.com/news/home/20240403640456/en/West-Point-Optical-Group-LLC-and-Vers%C3%A9a-Ophthalmics-Inc.-Announce-Partnership-Supply-Agreement-for-%C2%A0BIOVANCE%C2%AEand-BIOVANCE%C2%AE-3L-Ocular
We just need CLIA waiver approvals and these 86 locations will sell our products.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Verséa Ophthalmics is in Booth 346 in Boston this weekend at the #ASCRS2024.
https://ascrs.org/annual-meeting
Everyone is busy at Verséa Ophthalmics. Attending trade shows. Signing up customers. Signing exclusive supply agreements. This must be why no one has updated the LinkedIn page with all of the recent news.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_ascrs-2024-activity-7179073158124064769-eSBd?utm_source=share&utm_medium=member_android
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
This new customer may start TPOC next week according to this post.
Maybe everyone at Verséa Ophthalmics is so busy signing new customers they have not had time to post to social media?
https://www.linkedin.com/posts/kyledkluteod_optometry-optometry-optometrists-activity-7182089642018578432-SGx6?utm_source=share&utm_medium=member_android
Another #Biovance and #Biovance3L Verséa Ophthalmics supply agreement announcement.
https://www.linkedin.com/posts/ajblackston_west-point-optical-group-llc-and-vers%C3%A9a-activity-7181267958994759681-UyHG?utm_source=share&utm_medium=member_android
The new customer not yet announced by the Verséa Ophthalmics LinkedIn page is one of the 86 Pearle Vision clinics that will be using the Verséa Ophthalmics #Biovance and #Biovance3L products.
Obviously AXIM will eventually benefit from the Verséa Ophthalmics marketing agreement but it is interesting that Verséa Ophthalmics has another revenue stream outside of their relationship with AXIM. Verséa Ophthalmics has put a lot of thought and effort into their Tear-based Point-of-Care solution and their #TPOCTITAN image.
https://www.linkedin.com/posts/harminchima_we-are-excited-to-offer-state-of-the-art-activity-7181312124533493762-HK5P?utm_source=share&utm_medium=member_android
As an AXIM investor I am frustrated with only one new customer per week. I am also frustrated that AXIM appears to not have the knowledge and/or ability to create and submit the CLIA Waiver Application to the FDA. Is Mr Kurt Phinney still under contract with AXIM?
We need answers!!
This is huge for Verséa Ophthalmics but does not help AXIM at all, at least for now.
86 Pearle Vision clinics to offer Verséa Ophthalmics #Biovance and #Biovance3L products.
It seems Verséa Ophthalmics can create large revenue streams outside their relationship with AXIM.
https://www.linkedin.com/posts/jenniecrabbe_optical-chain-to-exclusively-offer-vers%C3%A9a-activity-7182094188467924992-1SgG?utm_source=share&utm_medium=member_android
Very interesting developments.
New customer was not announced yet by Verséa Ophthalmics.
https://www.linkedin.com/posts/harminchima_we-are-excited-to-offer-state-of-the-art-activity-7181312124533493762-HK5P?utm_source=share&utm_medium=member_android
Wildcards. AXIM has a few.
In my opinion one wildcard is the Parkinsons Disease test. If AXIM sells a new marketing agreement with a big pharma for the Parkinsons disease test that should come with $$ millions in Up-front revenue and residual revenue for each test.
In my opinion that only happens if AXIM needs the Up-front cash = Now. The Up-front cash would be needed because Cash-flow positive is pushed out with only one new customer per week. It should be obvious to everyone that the Tear-based Point-of-Care quantitative Parkinsons disease test would be a great addition to the Verséa Ophthalmics marketing agreement.
The second wildcard is CLIA Waiver approvals. However it seems like Mr Huemoeller mentioned in so many words that the CLIA Waiver Application has not been started yet. AXIM needs help from Verséa Ophthalmics and/or Mr Kurt Phinney to produce the CLIA Waiver Application and the comparison study.
I guess a third wildcard could be a merger or acquisition.
Outside of a few wildcards AXIM is not cashflow positive for months and months. These are my opinions. I really like the potential I see in AXIM. I may increase my position in AXIM in August or later when funds are hopefully available. The stock price probably does not move until AXIM is closer to cashflow positive.
Good luck to all.
Not investment advice.
Don't invest money needed for food or rent or happiness.
They need to to something Tex. They increased the AS on Silver Flume and on a subsequent date updated OTC Markets that there was no change. The 10K really has to address the OS/AS issues. If the AS is really 1Billion Shares it is hard to imagine that they have insufficient shares.
I'm not a good resource for that kind of information.
In my brain, I think about these small Biotech R&D companies in the same way i think about small precious metals Exploration companies.
Management is always trying to raise new money for the next drill program. The big spenders might buy "Preferred Shares" that can be converted later into Common shares. Either way, the Company has to make all of those transactions public knowledge.
Surely AXIM is forced to clear up the Derivative Liability insufficient shares mess by EOY reporting. ( I hope. ).
A question that I have regarding this stock and stocks in general that maybe someone here (Tex?) can address. If a company wishes to dilute by selling into the market or to a private investor to raise some cash where do the shares come from? Do they just need to be available in the AS or do they need to exist in the treasury? If that is the case how do they get there. Does it require a share issuance action like a S1 or is it an administrative action taken on by the company.
That link doesn't work for me but here is one that just worked. I got a log in message when I clicked your link and I don't have a log in account.
https://www.otcmarkets.com/filing/html?id=17417155&guid=11Q-knncHeK-B3h
Well what's it going to be? A 10K-NT at a minute to midnight or a surprise 10K? I'm usually overly optimistic about these things so I'll guess the 10K-NT.
Versea Health hired Stephen Gizzi as a regional sales manager for the New York metro area 5 months ago.
Yesterday Verséa Ophthalmics added a new paying customer from New York. Funny how that works.
Verséa Ophthalmics and Verséa Health are building a sales staff that has added new customers from New York to Seattle. From Cincinnati to Miami. Don't forget about the new customers in Colorado, Oklahoma, Texas, Georgia, and Missouri.
Most of these new sales managers have been in the EyeCare space for many years and already have customers they have built relationships with over the years.
In my opinion, if you want to build a brand new company from the ground up, you probably want to have qualified sales people in all of the major metro areas where your customers live and are doing business. Sure it seems slow right now adding just one customer per week. But just step back and look at where all of these new customers live. Verséa Ophthalmics is adding new customers from every region in the country.
My memory fails me right now.
I don't remember any customers from Los Angeles or Phoenix. A parent company was based in Dallas.
I think AXIM was very successful in choosing Verséa Ophthalmics to sell our Diagnostics tests.
Good luck to all.
Not investment advice.
Don't invest money needed for food or rent or happiness.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Instead of Questions here are a few Answers.
AXIM insiders and friendly parties have complete control of the company. Good, Bad or Ugly.
Catalina Valencia has been Legal Counsel for another startup company named Genentech Inc.
We have been told in the past that
Verséa Health and Verséa Ophthalmics are investors in AXIM. If the rights to the Tear-based Point-of-Care Parkinsons disease test are sold or subject to a negotiated marketing agreement to a Big Pharma then Verséa as part owners in AXIM will still benefit. Maybe Verséa does not have enough time or money to commit to the Tear-based Point-of-Care Parkinson Disease test.
More questions than answers - Continued.
As a Tear-based Point-of-Care (TPOC) Parkinson Disease test it seems a perfect fit with our existing Merchandising partner Verséa Ophthalmics. Right?
Are the $$ dollarss from one or more Big Pharma companies too big for Verséa Ophthalmics to even bid on this test?
Is it rock solid interest?
Is it backed up by $$Millions in a down payment AND residual $ dollars to AXIM for each test?
Something is going on that we can't see right now. More questions than answers.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Another paying customer has been added.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitan-tpoc-ded-activity-7179130900289351680-VhAU?utm_source=share&utm_medium=member_android
Website from new customer.
Manhattan New York apparently.
https://www.eyewise.com/our-eye-doctors/
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Exactly. Very confusing to not lead off with the revenue generating product that is already FDA cleared, and is being manufactured by an ISO-13485 certified manufacturer and is being marketed by a very knowledgeable team at Verséa Ophthalmics. Very interesting.
However the video does make me think that the Parkinsons disease test must be generating a lot of interest from one or more Big Pharma companies. Since it is a Tear-based Point-of-Care quantitative Diagnostics test one would think it would play well in the EyeCare space.
Is it rock solid interest?
Is it backed up by $$Millions in a down payment AND residual $ dollars to AXIM for each test?
More questions than answers.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Put your best foot forward?…raises eye rubbing questions.
We try not to give investment advice about AXIM. Probably most people who post here on the AXIM IHUB board have been invested in AXIM since the Covid days.
AXIM is generating revenue right now. Revenue seems to be growing every month. Apparently the CLIA Waiver Applications for the existing tests have not been submitted to the FDA yet. There is some type of process that needs to be followed to fill out the Waiver Application and also comparison studies with tests that are already have Approved CLIA Waivers. It is not a "simple" process. Is sounds like AXIM has not even started the process.
What does this mean for the business?
AXIM will have revenue grow at a slow pace until CLIA Waivers are submitted and approved.
AND/OR
AXIM could use the potential for a "Blockbuster" Parkinsons disease Tear based Point-of-Care test to generate both Up-front and residual revenue by signing a Marketing agreement with a large Pharma that can take the full responsibility of walking the test through the FDA process with the agreement that AXIM would still receive a fixed amount per test after it goes to market. That could happen.
A lot of things could happen over the next few months. Interesting times for AXIM right now.
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
The recent note creates 81.5 M shares years in the future. What I want to see is the conversion of the variable notes marking management's assessment that the stock has bottomed. Those have to be converted soon if the stock is indeed bottoming. It is of course a good sign that management accepted a new note in lieu of salary convertible into shares at 1 and 2 cents but my big indicator will be when the old variable conversion (TOXIC) notes convert. I have been avoiding using that word but since Tex used it I will too!
Blue Skys you were right about all of the Form 4’s AXIM would release
In the interview CEO JH said that he surmised that the FDA did not want patients and doctors to see precisely with the test that their antibody levels for Covid drop fast after the vaccine administrations. I thought that was interesting to hear about.
The stock price was 80 cents to $1.00 a few years ago when stockholders were hoping for the roll out of the Covid antibody level tests. We are now at a low of 1 cent for a few trades today.
He said that our dry eye disease tests are worth around 10X our current market cap. That does not include the Parkinson’s Disease test which seems like to me it would have a large market. There are likely other interesting tests that Sapphire is researching.
He mentioned the CLIA Waiver time for approval at the FDA is now targeted for 90 days and not the previous 8 or 9 months. That is good to hear about.
The stock chart shows a very dim prospect for this company but in actuality there are good reasons in my view to foresee and hope for a reasonable chance of success with AXIM.
Is it naive for me to feel this way? Maybe someone should describe here the probable likelihood of the reverse split risk in the near future. Then there are the subsequent offerings dilution risks.
There are other sometimes overlooked pitfalls of buying pre revenue small cap biotech companies. The tactics of shorts and toxic convertible debt schemes are also considerations.
Thanks.
From Yahoo
https://finance.yahoo.com/news/video-axim-biotechnologies-ceo-presents-130000171.html
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024...
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Link to the Benzinga 2024 Virtual Healthcare Summit 2024. AXIM has a prominent placement on this Website. Mr Huemoeller is advertising AXIM.
https://www.benzinga.com/events/virtual-healthcare-summit-2024/
If the #Parkinsons #TPOC #Diagnostics test is being used as leverage and as advertising to attract future financial relationships I have to think the Auer Precision relationship has created a prototype test that can be demonstrated in front of these potential relationships. Auer Precision advertises their R&D to help companies create real prototype examples to help speed products to market.
Have a good day!
Hashtags related to our company and partners.
Merchandising partner:
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
Manufacturing Partner:
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Parkinsons #TPOC #Diagnostics
#Lactoferrin #510K
510(k) Number K934473
#TotalIgE #510K
510(k) Number. K991316
Followers
|
105
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
5269
|
Created
|
04/29/14
|
Type
|
Free
|
Moderators Blue Skys Squirrel Hunter |
Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.
“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.
An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19. Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment.
Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.
AXIM® Biotech CEO John W. Huemoeller II commented, “Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.”
Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”
AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit www.AXIMBiotech.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |